Piramal Alternatives invests Rs 110 crore in Biodeal Pharmaceuticals : vimarsana.com

Piramal Alternatives invests Rs 110 crore in Biodeal Pharmaceuticals

Piramal Alternatives invested Rs 110 crore in Noida-based Biodeal Pharmaceuticals through convertible instruments. The funding will enhance infrastructure, technology, and a nutraceuticals manufacturing facility. Biodeal is a key contract manufacturing player, specializing in nasal sprays and achieving PIC/S approval.

Related Keywords

India , Anurag Kumar , Kalpesh Kikani , Biodeal Pharmaceuticals , Piramal Group , Credit Fund , Piramal Enterprises Etmarkets , Piramal Enterprises , Noida Based Biodeal Pharmaceuticals , Performing Credit , Inspection Co Operation Scheme , Piramal Alternatives , Nasal Sprays , Usfda , Performing Credit Fund ,

© 2024 Vimarsana